Anthropic shares early results from Claude in drug development: six partners including BMS, plus its own programs via Mithril Medicine
In an Oct 27 blog post, Anthropic described months of deep research partnerships between its life sciences team and six organizations (BigHat, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group), covering hit generation, lead optimization, manufacturing paperwork and clinical trial planning. It also said it acquired the one-person company Mithril Medicine to run its own programs for rare childhood muscular dystrophy. Anthropic stresses the work is mostly preclinical so far.

Key Takeaways
- Divergence Labs: Claude generated about 35,000 antibody designs in roughly a month, largely autonomously, yielding 3 hits that bind IgE and 20 that dislodge it, 3 of which beat the standard drug at dislodging (vendor-reported)
- BigHat: about 1,010 variants made and tested in about 10 weeks; the best versions bound over 10x more tightly, the cancer lead stayed in solution 18°C higher, and the other lead clumped over 100x more slowly
- Enveda: across 1,061 pages of manufacturing documents Claude caught all 11 issues humans found plus 7 they missed, cutting review time 89% (from over 25 hours to under 3)
- Generate Biomedicines: a CAR-T component designed with Claude Code was about 70% shorter and let immune cells make roughly 10x as many receptors
- Mithril Medicine acquisition: its founder used Claude to coordinate 11 external labs and went from idea to promising mouse results in under 18 months; human trials could start as soon as late 2028 (official blog)

